Premium
THERAPEUTIC HOTLINE: Alefacept in the treatment of hyperkeratotic palmoplantar psoriasis
Author(s) -
Lior Sagi,
Grigory Kriger,
Pnina Shemesh,
Joseph Shiri,
Felix Pavlotsky
Publication year - 2010
Publication title -
dermatologic therapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.595
H-Index - 68
eISSN - 1529-8019
pISSN - 1396-0296
DOI - 10.1111/j.1529-8019.2010.01361.x
Subject(s) - medicine , dermatology , plaque psoriasis , palmoplantar pustulosis , itching , psoriasis , hyperkeratosis , discontinuation
Plaque‐type palmoplantar psoriasis (PPP) is associated with marked morbidity and frequently resistant to conventional therapies. Patients with long‐standing plaque‐type PPP failing previous treatments were included and treated with a 12‐week intramuscular alefacept. The biweekly evaluation included hyperkeratosis, itching, and pain grading. In all of the seven treated patients significant to complete improvement in hyperkeratosis, pruritus and pain were observed, along with dose reduction or complete discontinuation of additional systemic treatments and without any recorded side effects. Alefacept should be considered as a therapeutic option for plaque‐type PPP.